As Global Payers Become Monopolies, Biopharma Need To Demonstrate Value Earlier – AusBiotech Conference
This article was originally published in PharmAsia News
Biopharma companies should define value propositions early and have a case for value differentiation at the discovery stage if they want to make a case to payers.
You may also be interested in...
Pfizer says that it won’t challenge NICE’s final rejection of Xalkori on cost-effectiveness and survival uncertainty grounds.
A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.